This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G10 | Special Copayment Reduction: V123 |
| B. Synonyms | Huntington disease, Huntington chorea |
| C. Adult onset | Very high likelihood of first onset in adulthood — typically presents in the 30s~50s; the juvenile form (JHD) presents in childhood |
| 1. History | First described by George Huntington in 1872; the molecular genetics era began in 1993 with identification of the CAG repeat expansion in the HTT gene (4p16.3) |
| 2. Causes | Pathological expansion of the CAG repeat in HTT gene exon 1 to 36 or more repeats; toxic gain of function of the mutant huntingtin protein |
| 3. Genetics | Autosomal dominant; incomplete penetrance at 36~39 repeats, full penetrance at 40 or more; anticipation prominent with paternal transmission |
| 4. General epidemiology | Prevalence in Western countries 5~10/100,000; relatively lower in Asia, including Korea; median age of onset in the 30s~50s |
| 5. Pathophysiology | Polyglutamine aggregates, selective damage to striatal medium spiny neurons, mitochondrial dysfunction, somatic CAG instability |
| 6. Symptoms | Triad of movement disorder (chorea → rigidity), cognitive decline (subcortical dementia pattern), and psychiatric symptoms (depression, obsessive-compulsive symptoms, psychosis) |
| 7. Signs | Choreiform involuntary movements, delayed saccade initiation, hyperactive deep tendon reflexes; in the late stage muscle rigidity, dysphagia, and dysarthria |
| 8. Screening | Family history-based predictive genetic testing (multistep genetic counseling mandatory); NfL and mHTT biomarkers under study |
| 9. Diagnosis | Molecular genetic testing of HTT CAG repeat number by PCR and long-read sequencing, UHDRS clinical assessment, caudate atrophy on brain MRI |
| 10. Treatment | Tetrabenazine/deutetrabenazine to suppress chorea, SSRIs and antipsychotics, clinical trials of ASO-based gene silencing therapy |
| 11. Prognosis | Mean survival 15~20 years after diagnosis; longer CAG repeats mean earlier onset and faster progression; aspiration pneumonia is the main cause of death |
| 12. Prevention | Preventing transmission of the pathogenic allele through preimplantation genetic testing (PGT-M), prenatal diagnosis, and genetic counseling |
| 13. References | Bates GP et al. Nat Rev Dis Primers 2015 and 9 other papers |
The history of Huntington disease begins in 1872, when the American physician George Huntington, having observed families on the eastern coast of Long Island for decades, gave the first systematic description in a paper titled "On Chorea." Based on his experience of following these families together with his father and grandfather, Huntington clearly summarized four features: adult-onset progressive involuntary movements, mental disturbance, dementia, and transmission within families. This description later became the origin of the disease's name.
From the late 19th to the early 20th century, reports of similar families followed from across Europe, and in the 1950s~60s neuropathological studies established that severe neuronal loss in the striatum, particularly the caudate nucleus and putamen, is the main lesion. In the 1960s~70s, drugs suppressing hyperkinesia, such as reserpine and tetrabenazine, were tested.
The turning point of the molecular genetics era was the discovery in 1983 by the research team of James Gusella of a disease-linked marker on the short arm of chromosome 4 (4p16.3). Building on this, after 10 years of international collaborative research, in 1993 the Huntington's Disease Collaborative Research Group identified CAG trinucleotide repeat expansion within exon 1 of the HTT gene as the cause. This was the first discovery in the group of polyglutamine diseases and provided a paradigm for research on many hereditary neurodegenerative diseases, such as spinocerebellar ataxias.
Since the 2000s, mouse and primate models have been established, accelerating research on pathogenic mechanisms, and in 2008 tetrabenazine received the first US FDA approval for chorea associated with Huntington disease. In 2017, deutetrabenazine was additionally approved. Clinical trials of antisense oligonucleotide (ASO)-based gene silencing therapy are currently under way.
The single cause of Huntington disease is pathological expansion of the CAG trinucleotide repeat sequence within exon 1 of the HTT gene, located at 16.3 on the short arm of chromosome 4 (4p16.3). The number of CAG repeats in healthy individuals is usually 9~35, and 36 or more makes the disease possible. Because CAG codes for the amino acid glutamine, the repeat expansion results in an abnormally long polyglutamine (polyQ) tract in the huntingtin (HTT) protein.
The HTT protein normally plays various roles, including transport of intracellular organelles, maintenance of synaptic function, and promotion of BDNF production. When pathological polyQ expansion occurs, the protein's conformation is altered, forming nuclear and cytoplasmic aggregates, and these aggregates disrupt the proteasome and autophagy pathways, causing a toxic gain of function. At the same time, loss of normal HTT function is also known to contribute to neuronal vulnerability.
Proposed mechanisms of pathological CAG expansion include slipped-strand errors during DNA replication and somatic instability during the repair process. Repeat expansion is prone to occur in germ cells, particularly during spermatogenesis, so anticipation is prominent with paternal transmission. CAG repeat length shows an inverse correlation with age of onset, and the juvenile form (JHD) appears at 55 or more repeats. Environmental factors alone do not cause the disease, but physical activity, stress, and comorbidities can affect the rate of progression.
Recent large-scale GWAS studies have shown that variants in DNA mismatch repair genes such as MSH3 modulate somatic CAG instability and can advance or delay the age of onset by years. This suggests that modifier gene pathways may be therapeutic targets, and MSH3 inhibition strategies are being studied at the preclinical stage.
Huntington disease is caused by an autosomal dominant mutation of the HTT gene. A single pathogenic allele is sufficient to cause the disease, and the clinical phenotypes of heterozygotes and homozygotes do not differ greatly. This follows the typical dominant toxic gain-of-function mechanism. There are reports that homozygotes have a somewhat earlier age of onset, but such cases are rare.
Clinical categories by CAG repeat number are as follows. 9~26 repeats: normal, unchanged when transmitted to offspring. 27~35 repeats: intermediate allele; the individual does not develop the disease, but pathological expansion in children is possible because of germline instability. 36~39 repeats: reduced penetrance; onset only in some individuals, usually at a later age. 40 or more repeats: full penetrance; the disease will inevitably develop if the person lives long enough. 55 or more repeats: associated with the juvenile form (JHD).
Genetic anticipation is marked with paternal transmission and is caused by somatic instability during spermatogenesis. Maternal transmission shows relatively little change in repeat number. Because the presence or absence of CAA interruptions within the CAG repeat affects the interpretation of the actual pathogenic repeat number, the importance of diagnosis by state-of-the-art long-read sequencing is emphasized. Some patients without a family history are explained by de novo expansion from carriers of an intermediate allele.
Transmission of the pathogenic allele to children can be prevented through preimplantation genetic testing (PGT-M) and prenatal diagnosis. For at-risk individuals who do not want predictive genetic testing, there is also a non-disclosing linkage analysis method (exclusion testing). Under international guidelines, predictive testing of minors is in principle not recommended unless there is medical benefit.
The worldwide prevalence of Huntington disease is about 5~10/100,000 people and is relatively high in populations of European descent. Prevalences of 10/100,000 or more are reported in the UK, Canada, the US, and Australia, while in populations of Asian and African descent it is lower, at 1~4/100,000. In East Asia, including Korea, prevalence is also lower than in Western countries, and the number of patients in Korea is estimated to be in the hundreds.
The median age of onset is 30~50 years, with a mean of about 40 years. About 5~10% of all patients have the juvenile form (JHD), with onset before age 21, usually with 55 or more CAG repeats. Late onset after age 60 also occurs in up to about 10%. The male-to-female ratio is equal, and differences between races are due to differences in pathogenic allele frequency and founder effects.
The total number of patients in the US is estimated at about 30,000~40,000, and the number of presymptomatic carriers of the pathogenic allele at about 200,000. The incidence is about 1~3/100,000/year. With wider availability of genetic testing, the number of individuals identified before onset is increasing, and enrollment of these individuals in clinical trials is also expanding. High-prevalence areas due to founder effects are also known, such as near Lake Maracaibo in Venezuela.
In Korea, rare disease registration and management are carried out under Special Copayment Reduction code V123, and the status of registered patients can be determined from Health Insurance Review & Assessment Service (HIRA) data. Because of the nature of rare diseases, diagnostic delay is common, and the actual number of prevalent patients may be greater than the number of registered patients.
The core pathophysiology of Huntington disease is the toxic gain of function of mutant huntingtin (mHTT) with a pathological polyglutamine (polyQ) chain. mHTT forms abnormal protein aggregates, creating nuclear inclusions and cytoplasmic aggregates, and sequesters binding partners such as transcription factors and heat shock proteins, broadly disrupting gene transcription programs. The function of transcriptional regulators such as SP1, CBP (CREB-binding protein), and TAFII130 is impaired.
Medium spiny neurons (MSNs) of the striatum are the first to be severely damaged in Huntington disease. MSNs are GABAergic inhibitory neurons that integrate nigrostriatal dopamine signals and corticostriatal glutamate signals, and excitotoxicity arises in both pathways, making MSNs selectively vulnerable. Indirect pathway MSNs are lost earlier than direct pathway MSNs, producing early chorea, and in the late stage both pathways are damaged, with a shift to rigidity and hypokinesia.
Mitochondrial dysfunction is also an important mechanism. mHTT binds directly to mitochondrial membranes or inhibits the activity of energy metabolism complexes II and III, increasing oxidative stress. A vicious cycle has also been confirmed in which damage to the autophagy and ubiquitin-proteasome pathways makes clearance of mHTT aggregates insufficient. Reduced striatal transport and secretion of BDNF, which reduces the supply of survival trophic factors to MSNs, also contributes to pathogenesis.
It has recently been shown that somatic CAG repeat instability contributes directly to the timing of onset and progression. In particular, somatic CAG expansion continues to increase in the striatum, and variants in DNA mismatch repair genes such as MSH3 accelerate it. This suggests that modifier gene pathways are a major factor explaining clinical heterogeneity between individuals and is drawing attention as a therapeutic target.
The clinical triad of Huntington disease is movement disorder, cognitive decline, and psychiatric symptoms. The three domains progress in combination and gradually, eventually causing loss of overall daily functioning. In the premanifest phase, mild slowing of cognitive speed, reduced concentration, and emotional instability may precede clear motor symptoms, and this preclinical period sometimes lasts from several years to more than 10 years.
The early motor symptoms are choreiform involuntary movements, beginning in the fingers, toes, and face and gradually spreading proximally and to the whole body. In the early stage, patients may not notice them themselves, or they may be mistaken for tension-relieving behaviors. As the disease progresses, chorea decreases, and muscle rigidity, bradykinesia, and postural instability come to the fore. Dysphagia causes aspiration pneumonia and is a main cause of death.
Cognitive symptoms follow a subcortical dementia pattern, with prominent slowing of processing speed and impairment of working memory and executive function, while language function is relatively preserved. Reduced visuospatial ability, reduced insight, and impulse control disorders are also common. Psychiatric symptoms occur in 30~70% of patients, with depression, anxiety, obsessive-compulsive symptoms, and irritability the most common. Psychosis occurs in 5~10%. The risk of suicide is 4~6 times higher than in the general population, so psychiatric monitoring is essential.
In the juvenile form (JHD), rigidity, seizures, and cognitive decline are more prominent than chorea, and declining academic performance may appear as an early sign. Cerebellar ataxia, seizures, and facial dystonia show a pattern different from the adult form, progression is faster, and survival is shorter. Weight loss occurs at all stages of the disease and can lead to malnutrition.
On neurological examination, the characteristic signs of Huntington disease include, besides chorea, eye movement abnormalities, increased reflexes, and postural instability. Choreiform involuntary movements occur suddenly in the facial muscles, limbs, and trunk with varying amplitude and direction and disappear during sleep. Gait shows an irregular pattern (dancing gait), and the risk of falls increases.
Eye movement abnormalities appear from the early stage of the disease, typically delayed initiation of voluntary saccades and inability to suppress reflexive saccades. Impaired smooth pursuit eye movements and reduced fixation ability are also observed. These eye movement abnormalities are used as sensitive signs in preclinical assessment.
Deep tendon reflexes are hyperactive (hyperreflexia) early but may decrease in the late stage. Pyramidal tract signs such as a positive Babinski response may appear. In the late stage, the disease progresses to muscle rigidity, dysphagia, dysarthria, and complete dependence while fully conscious. The Unified Huntington's Disease Rating Scale (UHDRS) is the standard clinical tool for quantifying motor, cognitive, behavioral, and functional capacity. Body weight loss correlates with disease progression and is also used as a prognostic indicator.
The diagnostic confidence level is classified into grades 1~4 based on the UHDRS motor assessment total score, and grade 4 (99% confidence) defines clinically manifest Huntington disease. Without a family history, diagnosis is difficult on clinical signs alone, and it must be confirmed by molecular genetic testing.
Screening for Huntington disease falls into two contexts: confirmation of symptoms and presymptomatic predictive genetic testing. Presymptomatic predictive testing is performed in accordance with globally established psychosocial guidelines, on the premise of rigorous genetic counseling and a process of psychological preparation. The international Huntington disease association (IHDG) and national genetics societies in principle do not recommend presymptomatic testing of minors unless there is medical benefit.
Family history screening is the most basic approach. When one parent has been diagnosed with Huntington disease, each child has a 50% chance of carrying the pathogenic allele. For these at-risk individuals, a multistep process is recommended, including pre-test genetic counseling, psychiatric evaluation, and confirmation of an individual support system. Non-disclosing linkage analysis (exclusion testing) is also available for at-risk individuals who do not want predictive testing.
For biomarker-based preclinical monitoring, quantification of mutant huntingtin (mHTT) in cerebrospinal fluid and plasma and measurement of cerebrospinal fluid neurofilament light chain (NfL) are used at the research stage. NfL is a marker reflecting neuronal damage that begins to rise before onset and is emerging as a surrogate endpoint in clinical trials. Brain MRI measurement of caudate volume is also used as an imaging biomarker that captures preclinical changes.
Newborn screening is not ethically recommended because of the adult-onset nature of Huntington disease and the current absence of effective preventive treatment. However, if next-generation gene therapy clinical trials succeed, screening policy may be reconsidered along with early intervention strategies. Prenatal diagnosis and PGT-M should be actively discussed at the family planning stage.
Huntington disease is confirmed by molecular genetic testing quantifying the CAG repeat number of the HTT gene. The diagnosis is established when 36 or more CAG repeats are found in a patient whose clinical symptoms and family history are consistent. The standard diagnostic method is PCR-based fragment length analysis, and for long repeats (>60), long-read sequencing or repeat-primed PCR is needed. When interpreting test results, not only the CAG repeat number but also the presence of CAA interruptions within the repeat should be considered.
For clinical assessment, quantification of motor, cognitive, behavioral, and functional capacity using the UHDRS is standard. Diagnostic confidence level 4 must be met on motor assessment for clinically manifest Huntington disease to be defined. Neuropsychological tests (MMSE, MoCA, a neuropsychological test battery) assess the domains and severity of cognitive decline.
Brain MRI provides imaging findings supporting the diagnosis, with enlargement of the frontal horns of the lateral ventricles due to caudate atrophy being characteristic. Putaminal atrophy is also present. MRI volumetry is used to measure the rate of progression for research purposes. Reduced striatal metabolism can be confirmed on FDG-PET, but this is not required for clinical diagnosis.
For the differential diagnosis, other diseases causing chorea must be excluded. Neuroacanthocytosis, Wilson disease, HDL types 1, 2, and 4 (PRNP, JPH3, and TBP/SCA17 genes, respectively), anti-NMDAR encephalitis, lupus-associated chorea, tardive dyskinesia, and others are subjects of differentiation. When there is no family history and CAG testing is negative, a Huntington Disease-like syndrome gene panel test is helpful.
There is currently no proven treatment that halts disease progression in Huntington disease, and treatment focuses on symptom control and maintaining quality of life. A comprehensive approach through a multidisciplinary team (neurology, psychiatry, rehabilitation medicine, nutrition, speech therapy, social work) is the standard.
The first-line drug for controlling chorea is tetrabenazine (TBZ). It inhibits vesicular monoamine transporter 2 (VMAT2), depleting synaptic dopamine. The main side effects are depression, parkinsonism, and somnolence, and it is contraindicated in patients with suicidal tendencies. Deutetrabenazine is a deuterated derivative of TBZ that provides more stable blood concentrations and improved tolerability. Valbenazine, also a VMAT2 inhibitor, has recently been approved. Antipsychotics such as haloperidol, and clonazepam, can also be used for chorea.
For psychiatric symptoms, SSRIs are mainly used for depression, anxiety, and obsessive-compulsive symptoms. For irritability, valproic acid and atypical antipsychotics are used. For psychosis, atypical antipsychotics such as quetiapine and olanzapine are preferred. For sleep disorders, melatonin and clonazepam are considered.
In the field of disease-modifying treatment, HTT gene silencing therapy is drawing the most attention. The antisense oligonucleotide tominersen confirmed mHTT reduction in phase 3 in 2021, but clinical benefit was insufficient, and studies optimizing the dosing interval are under way. RNA interference (RNAi)-based therapies, zinc finger transcription factors, and CRISPR-based approaches are at the preclinical and early clinical stages. There is also evidence that motor rehabilitation and cognitive training help maintain function.
Huntington disease is a progressive neurodegenerative disease with no current cure, so continuous functional decline after diagnosis is inevitable. The mean survival from diagnosis to death is 15~20 years, with large individual differences. Longer CAG repeats tend to mean earlier onset and faster progression, but there is considerable heterogeneity in age of onset and course even with the same CAG repeat number.
The disease is divided into early (about 5~8 years), middle (about 5~8 years), and late (about 2~5 years) stages. In the early stage, social and occupational functioning is often maintained, but subtle cognitive changes and emotional instability begin. In the middle stage, chorea and cognitive decline become marked, and independent living becomes increasingly difficult. In the late stage, overall function declines markedly, resulting in complete dependence on care.
The most common cause of death is aspiration pneumonia, and trauma from falls, malnutrition, and suicide are also important causes. The juvenile form (JHD) is characterized by faster progression and shorter survival (8~12 years) than the adult form. Active multidisciplinary supportive care, particularly nutritional management and prevention of aspiration, contributes to prolonged survival. Early integration of genetic counseling and palliative care is important for improving the quality of life of patients and families.
Fundamental prevention of Huntington disease is blocking the transmission of the pathogenic allele between generations. Preimplantation genetic testing (PGT-M) analyzes the CAG repeat number of the HTT gene in embryos obtained through in vitro fertilization and transfers into the uterus only embryos with normal alleles, enabling pregnancy without transmission of the pathogenic gene.
When PGT-M is not wanted or not available, prenatal diagnosis is an alternative. The CAG repeat number in fetal DNA can be analyzed through chorionic villus sampling (CVS) at 10~13 weeks of pregnancy or amniocentesis at 15~18 weeks. Non-disclosing linkage analysis (exclusion testing) is also available for at-risk individuals who do not want predictive testing. All family planning decisions should be supported by comprehensive genetic counseling and psychological support.
Lifestyle management before onset also has preventive significance. There is evidence from animal and observational studies that regular aerobic exercise may have a neuroprotective effect through increased BDNF. A cognitively active lifestyle is recommended in terms of cognitive reserve. Clinical trials of preventive disease-modifying treatment (including HTT silencing therapy) in preclinical patients are under way, and prevention or delay of onset may become possible in the future.